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The multidrug-resistance associated protein 1 (MRP1) and multidrug-resistance 
associated protein 2 (MRP2) are membrane transporters responsible for the efflux of 
endogenous compounds, a variety of drugs, along with other xenobiotics.  They are two 
of the most highly expressed transporters, but are localized on opposite sides of polarized 
membranes:  MRP1 is on the basolateral side, while MRP2 is on the apical side.   Since 
MRP1 and MRP2 can eliminate such a wide variety of compounds from cells, thereby 
reducing their half-life, assessing the transport of highly prescribed pharmaceuticals via 
MRP transporters either alone or in mixtures is important to determine the potential for 
drug-drug interactions.  MDCK cells transfected with the MRP1 and MRP2 gene were 
used to assess drugs as potential substrates by examining their differential toxicity, 
accumulation, and efflux.  Based upon initial screening assays, three high-use 
pharmaceuticals, fosinopril, loratadine, and desloratadine were assessed, along with the 
known substrates vincristine and methotrexate as positive controls.  MRP1-
overexpressing cells were 1.4-fold less sensitive to the toxicity of loratadine and 2-fold 
less sensitive to fosinopril.  MRP2-overexpressing cells were 2.4-fold less sensitive to 
fosinopril than controls, while cells showed no difference in sensitivity to desloratadine.  
We then conducted accumulation/efflux assays to help substantiate that these compounds 
were indeed substrates for the MRP1 and MRP2 transporters.  The positive control, 
vincristine, was transported out of the MRP1-overexpressing cells more rapidly, with 
56% of the compound remaining compared to 85% of the vincristine remaining in the 
MDCK cells.  The other positive control, methotrexate, accumulated 1.5-fold less in 
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MRP2 cells compared to controls.  MRP1 and MRP2 only showed slight differences in 
their ability to transport loratadine.  MRP1 cells retained 52% of the loratadine and 53% 
remained in MRP2 cells compared to 63% remaining in control cells.  MRP2-
overexpressing cells effluxed desloratadine significantly more rapidly, as 56% of the 
accumulated desloratadine remained in MRP2-overexpressing compared to 66% retention 
in the MDCK cells.  More impressively, fosinopril only retained 13% in MRP2 cells 
while the MDCK cells retained 60%.   
 
Since fosinopril appeared to be a good substrate for MRP2, we used it to perform 
mixture assays to assess the possibility of drug-drug interactions.  Cells were incubated 
with fosinopril along with loratadine, desloratadine, or methotrexate to determine if the 
second drug would increase the retention of fosinopril.  When fosinopril was combined 
with desloratadine, its retention was increased by 2-fold, with loratadine, its retention was 
increased by 4.7-fold, and with methotrexate the retention was increased by 2-fold.  The 
increase in retention with multiple drugs likely indicates that a drug-drug interaction is 
occurring.  We then dosed wild-type and Mrp2 knockout mice with methotrexate, a 
known Mrp2 substrate, and fosinopril.  In mice lacking Mrp2, fosinopril and 
methotrexate levels are increased in the serum and the kidneys, which suggest that Mrp2 
is needed to eliminate fosinopril.  This also suggests that with the absence of Mrp2 there 
is a shift from the fecal to urinary elimination, which could potentially lead to toxic levels 
if no compensatory mechanism takes over.  The body’s ability to adapt to changes made 
by drug-drug interactions is vital for survival.  Assessing the transport of highly 
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prescribed pharmaceuticals by MRP transporters is important to determine the potential 
for drug-drug interactions, and will aid clinicians in minimizing drug toxicity.  
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A large variety of the anionic substrates are transported across the cellular 
membranes through the use of ABC transporters.  ABC transporters are members of one 
of the largest super families, containing more than 48 members, which all require ATP to 
mediate transport (Dean, 2001).  The MRP family (also known as ABCC), along with the 
cystic fibrosis regulator (ABCC7) makes up this MRP subfamily that contains 12 full 
transporters.   Functioning in the elimination of many of the endogenous and xenobiotic 
compounds, some of the compounds transported by these proteins are bile salts, lipids, 
steroids, anticancer agents and drugs (Roger et al., 2006).   
 
In order for many pharmaceuticals and physiological substrates to be excreted by 
the body, they first have to go through several biotransformation steps.  Many times this 
multistep biotransformation process involves phase I and phase II enzymes.  In the first 
phase, substances are hydrolyzed, reduced, or oxidized to add a functional group to the 
compound, which is oftentimes done by a family of enzymes called the cytochrome 
P450s.  Following this first phase, one transformation substance will go through a 
conjugation reaction with a glucuronide, sulfate, or glutathione group added on by phase 
II enzymes.  Adding on one of these cofactors make the lipophilic compounds more 
water-soluble and more likely to be excreted via the urine or the bile.  This addition of a 





Every year there are over 2.2 million people injured by prescription drugs alone 
(Watson et al., 2008).  With the MRP’s having such a diverse substrate specificity and 
ubiquitous location in the body, there are many situations in which potential drug-drug 
interactions could result.  The most studied examples of drug-drug interactions involve 
situations where two drugs are metabolized by the same enzyme.  P450s are one such 
superfamily of enzymes that are extremely important in the phase I metabolism of many 
drugs (reviewed in Omari et al, 2007).  Certain drugs may increase the amount of P450s 
present and speed up the oxidation and clearance of a second drug.  A good example of 
this type of drug-drug interaction is the induction of CYP2C9 by rifampin (Zakia, 2008).  
Among the substrates of CYP2C9 is the anticoagulant warfarin.  If someone was 
depending on warfarin acting as a blood thinner, increasing its metabolism by the 
addition of a second drug could potentially result in a blood clot, stroke, or heart attack 
(Zakia, 2008).  A search of the literature reveals that most published drug-drug 
interactions are mediated via P450s, as they describe how inactivation of CYP’s could 
result in clinically relevant drug interactions and adverse drug reactions.  Drug-drug 
interactions can result in a prolonged half-life of the compound or a higher concentration 
in the organs, which, if not put in check, can lead to toxic effects (Leucuta et al., 2006; 
Zhou et al., 2006).  However, there are few studies investigating drug-drug interactions 
via phase II enzymes. 
 
For the past few decades there have been many advances in the characterization 
and function of these transport proteins.  Their role in the absorption, distribution, 
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metabolism and excretion of drugs, and endogenous compounds and other xenobiotics 
through the liver, kidneys and other tissues is very important (van de Water et al., 2005).  
Two of the biggest players involved in therapeutic compounds and toxicologically 
relevant drug resistance and in drug transport are the MRP1 and MRP2 proteins.  They 
pump in opposite directions (basolateral vs. apical) and have been shown to contribute to 
drug elimination (Keppler et al., 1997; Kruh et al., 2001; Zhou et al., 2008).   
 
MRP1 (ABCC1) 
Multidrug resistance-associated protein 1 was first identified because of its ability 
to eliminate cytotoxic
 
drugs from lung tumor cells (Cole et al., 1992).  These cells were 
selected by being exposed to the anthracycline doxorubicin repeatedly (Cole et al., 1992).  
Although discovered with the use of a single drug, MRP1 cells are also resistant to a 
large variety of structurally unrelated anticancer compounds, such as vincristine, 
daunorubicin, and methotrexate and can transport physiological products, such as 
conjugated steroid hormones and bile salts. MRP1 can also transport drugs, such as 
flutamide, (an antiandrogen), ritonavir, (an antiviral), or difloxacin and grepafloxacin, 
(both antibiotics) (reviewed in Munoz et al., 2007; Sasabe et al., 2004; van de Water et 
al., 2005; Zaman et al., 1994).  MRP1 expression is restricted to the basolateral side of 
certain tissues, including kidney, lung, intestine, brain, testis, macrophages, epithelial 
cells, and hepatocytes, although the expression of MRP1 in the liver is somewhat low 
(Flens et al., 1996; van de Water et al., 2005; Wijnholds et al., 1998).  MRP1’s highest 
expression can be found in the kidney, with expression in the distal tubule, collecting 
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duct tubule, and loop of Henle (Rothnie et al., 2008).  MRP1 overexpression has been 
seen in a variety of solid tumors, such as in the lung, breast, and prostate, which shows to 
be problematic when pharmaceutical therapy is administered.  The overexpression of the 
MRP1 increases the elimination of therapeutic compounds, thereby decreasing their 
effectiveness (Munoz et al., 2007). 
 
MRP1’s ability to transport a variety of conjugated substrates is confirmed by in 
vitro and in vivo studies using models lacking Mrp1.  For example, one study showed that 
mouse cell lines lacking the Mrp1 gene were substantially more susceptible to drugs 
compared to wild-type mice cells lines.  Some of the drugs examined were 
epipodophyllotoxins, whose toxicity increased 4 –7-fold in the knockout cell lines, 
camptothecins (3-fold increase), arsenite (4-fold increase), anthracyclines (6 –7 fold 
increase), and vincristine (28-fold increase in toxicity) (Allen et al., 2000).  Another 
study showed that there is elevated intracellular accumulation and a decreased excretion 
of leukotriene C4 (an MRP1 substrate).  As a result, the secretion of this product 
decreased to about 1/4 of normal levels found in cultured bone marrow mast cells of Mrp 
-/-
 mice (Wijnholds et al., 1997).  Mrp1
-/-
 mice showed a decrease in body weight and 
fatalities at etoposide concentrations that were not normally fatal to wild-type mice 
(Wijnholds et al., 1997).   In a study done on the drug grepafloxacin, an oral broad-
spectrum quinoline antibacterial, the ratio of the drug found in the tissue compared to the 
drug found in the plasma was significantly higher in the heart, trachea, kidney, spleen, 
and brown fat of Mrp1
-/-
 mice than the drug found in wild-type mice (Sasabe et al., 2004).  
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These findings demonstrate the importance of the MRP1 protein and its role in 
eliminating certain compounds. 
 
MRP2 (ABCC2) 
Although the function of the second member of the ABCC family had been 
known for years, the discovery of its gene did not occur until 4 years after the discovery 
of MRP1 (Borst et al., 2000).  The MRP2 transporter was originally known as the 
canalicular multispecific organic anion transporter (cMOAT).  TR-/GY rats were used for 
many years to study defects in the excretion of many negatively charged, amphiphilic 
organic anions, such as bilirubin-glucuronide (Borst et al., 2000), and are now known to 
have defective mutations in their ABCC2/cMOAT/MRP2 gene (Paulusma et al., 1996).  
The TR- rat’s phenotype is similar to that of patients with Dubin-Johnson syndrome, 
which is characterized by jaundice, the result of chronic conjugated hyperbilirubinemia, 
caused by impaired hepatobiliary elimination of many organic compounds (Paulusma et 
al., 1996; Paulusma et al., 1997).  
 
The Mrp2 protein product has been shown to be expressed on the apical 
membrane (Keppler et al., 1997).  MRP2 tends to be more restricted in its tissue 
distribution than MRP1, being localized in the liver, gallbladder, kidney, small intestine, 
colon, placenta, and lung (Bandler et al., 2008).  The coordinate induction of MRP2 and 
several phase II enzymes is, in part, regulated by a nuclear transcription factor termed the 
constitutive androstane receptor (CAR) (Johnson et al., 2002; Kast et al., 2002).  MRP2 
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functions as a transporter of a variety of drugs and xenobiotics, such as bilirubin, sulfated 
bile salts, non-conjugated compounds, and cytotoxic agents: etoposide, vinblastine, 
cisplatin, methotrexate, doxorubicin, and epirubicin (Bandler et al., 2008; reviewed in 
van de Water et al., 2005).  MRP2, along with MRP1 and MRP3, shows considerable 
overlap in the substrate specificity, which is supported by the fact that it has a high 
amino-acid homology (Bakos et al., 2000).   The MRP2 was found to eliminate 
glutathione conjugates like leukotriene C4, S-(2, 4-dinitrophenyl)-glutathione, and N-
ethylmaleimide glutathione, along with glutathione (reviewed in van de Water et al., 
2005).    Like MRP1, MRP2 transports GSH and GSSH, and therefore is also thought to 
help protect the cell from oxidative stress (Roger et al., 2006).   
 
The MRP2 transporters have also shown to be expressed in various colorectal, 
hepatic, mesothelial, lung, ovarian, and leukemic cancer cells (Hoffmann et al., 2004).  
This leads to the assumption that MRP2 may be a potential obstacle in the use of certain 
chemotherapeutic agents.  A clinical study on breast cancer indicated that the use of 
Ionafarnib, a MRP2 inhibitor, along with cisplatin and/or 5-fluorouracil, resulted in 
reduction of the chemotherapy dosage and could become less toxic (Hoffmann et al., 
2004).   
 
As stated previously, much of what we know about the MRP2 protein was 
performed on TR- rats.  The TR- rats are compromised in their ability to effectively 
eliminative compounds via biliary secretion.  In a study on TR- rats, it was found there 
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was dramatic reduction in the rats’ ability to eliminate bromosulfophthalein by 15 %, 
dibromosulfophthalein by 50 %, and
 
indocyanine green by 75%, compared to that of 
normal levels (Jansen et al., 1993).  Although the original finding of the MRP2 
transporter was done in rats, there have been many studies done with mice.  For example, 
after the food-derived, oral administration of carcinogens PhIP (2-amino-1-methyl 6-





 mice versus wild-type mice.  In the same study there was a 1.7-fold increase in 





 mice versus wild-type mice, suggesting that Mrp2 may be reducing exposure to 
these compounds (Vlaming et al., 2006).  The Mrp2-deficient mice displayed decreased 
total bilirubin and glutathione in bile and increased levels of bilirubin in urine, indicating 
that urinary excretion may serve as an alternate excretion pathway for certain compounds 
in these mice (Vlaming et al., 2006).  In a study on spiramycin, which is used to treat 
respiratory infections, it was found that there was a 10-fold decrease in the rate of biliary 
excretion of spiramycin in Mrp2 knockout mice (Xianbin et al., 2007).  It has been shown 
that Mrp2 is one of the major regulators of biliary elimination of methotrexate (MTX) 
and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) in mice.  In this study it was 
found the up-regulation of Mrp2, along with the absences of the breast cancer resistance 
protein, another important anionic transporter, mice reduced biliary excretions of MTX 
and/or 7OH-MTX, which resulted in increased plasma levels of 7OH-MTX.  Levels of 
MTX in the kidneys also increased by 7-fold and liver levels of 7OH-MTX increased 90-




Assessing the transport of highly prescribed pharmaceuticals via MRP 
transporters either alone or in mixtures is important to determine the potential for drug-
drug interactions.  In the present study, we examined fosinopril, an angiotensin 
converting enzyme (ACE) inhibitor, loratadine and desloratadine, both antihistamines, to 
determine if they were substrates for the MRP transporters, and if so, whether they could 
alter the transport and toxicity of one another.  The pharmaceuticals of interest all have a 
high molecular weight, multiple rings, and are excreted from the body predominantly as 
conjugates.  The aim of this study was to examine whether these drugs interact by 
inhibiting one another’s excretion from cells via the multidrug resistance-associated 
proteins 1 and 2.    
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The multidrug-resistance associated protein 2 (MRP2) is a membrane-bound 
transporter responsible for the efflux of a variety of drugs and endogenous compounds.  
MDCK cells transfected with the human MRP2 gene were used to assess whether several 
highly used pharmaceuticals were potential substrates by examining their differential 
toxicity, accumulation, and efflux.  Fosinopril, an ACE inhibitor, was 2.4-fold less toxic 
to the MRP2 transfected cells compared to mock transfected cells, suggesting that 
fosinopril is a potential MRP2 substrate.   In addition, fosinopril was effluxed more 
rapidly, as the MRP2 cells only retained 13% of the dosed fosinopril after 20 minutes 
compared with 60% retained in the control cells.  To determine whether fosinopril might 
contribute to a drug-drug interaction, fosinopril efflux was examined in combination with 
several other known or suspected MRP2 substrates.  When fosinopril was coincubated 
with desloratadine, its retention was increased by 2-fold; with loratadine, its retention was 
increased by 4.7-fold, and with methotrexate, its retention was increased by 2-fold.  The 
increases in retention with multiple drugs likely indicate that a drug-drug interaction is 
occurring.  To further clarify whether fosinopril was a substrate for Mrp2, we dosed wild-
type and Mrp2 knockout mice with the known Mrp2 substrate methotrexate and 
fosinopril.  In mice lacking Mrp2, fosinopril and methotrexate levels were increased in 
the serum and the kidneys, which suggest that the lack of Mrp2 favors fosinopril 
excretion through the urine rather than the feces.  Assessing the transport of highly 
prescribed pharmaceuticals by MRP transporters is important to determine the potential 








1.  Introduction:  
Multidrug resistance-associated protein 1 and 2 (MRPs) are membrane-bound 
transporters that efflux a variety of drugs, other xenobiotics, as well as endogenous 
compounds (Homolya et al., 2003; Kruh et al., 2007; van de Water et al., 2005).  
Substrates for MRP1 include a large variety of structurally unrelated anticancer 
compounds such as doxorubicin, vincristine, daunorubicin, colchicines, and etoposide, 
physiological products, such as conjugated steroid hormones, leukotriene C4, and bile 
salts, and drugs such as grepafloxacin, (Allen et al., 2000; Bakos et al., 2000; Cole et al., 
1994; Jedlitschky et al,. 1997; Sasabe et al., 2004; Zaman et al., 1994) saquinavir 
(Williams et al., 2002), chloroquine (Vezmar et al., 1998), and ethacrynic acid (Zaman et 
al., 1996).  In vivo studies with mice lacking Mrp1 have confirmed some of these 
substrates.  For example, Mrp1
-/-
 mice have significant increases in the levels of the 
antibiotic grepafloxacin in the heart, trachea, kidney, spleen, and brown fat compared to 
wild-type mice (Sasabe et al., 2004).  The secretion of leukotreine C4 is diminished in 
cultured bone marrow mast cells of Mrp1
 -/-
 mice and these mice are hypersensitive to the 
toxicity of etoposide, which damages the mucosal layer of the tongue and cheek, and 
inhibits spermatogenesis (Wijnholds et al., 1997; Wijnholds et al., 1998).   
 
MRP2 and MRP1 show considerable overlap in the substrate specificity, since 
they have a high amino acid homology (Bakos et al., 2000).  MRP1 is expressed in most 
tissues, including the kidney, lung, intestine, brain, testis, macrophages, and hepatocytes, 
and it is localized to the basolateral side of polarized epithelial cells (Flens et al., 1996; 
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van de Water et al., 2005; Wijnholds et al., 1998). The MRP2 protein product is 
expressed on the apical membrane (Keppler et al., 1997), and tends to be a more 
restricted in its tissue distribution than MRP1, being localized in the liver, gallbladder, 
kidney, small intestine, colon, placenta, and lung (Bandler et al., 2008).   Like MRP1, 
MRP2 also transports a variety of physiological substrates and drugs, such as bilirubin, 
sulfated bile salts, etoposide, methotrexate, adefovir, chloroquine, loperamide, 
naringenin, sulfusalazine, and tamoxifen (Bakos et al., 2000; Jedlitschky et al,. 1997; 
Pedersen et al., 2008).  Other pharamaceuticals, such as saquinavir (Williams et al., 
2002), docetaxel (Zimmermann et al., 2008), pravastatin (Matsushima et al., 2005), 
cyclosporin A (Masahiro et al., 2005), lopinavir (Agarwal et al., 2007), acetaminophen 
(Xiong et al., 2000), temocaprilat (Ishizuka et al., 1997), enalapril (Liu et al., 2006), and 
several antibiotics including cefbuperazone, cefoperazone, ceftriaxone, cefpiramide, 
benzylpenicillin, and moxifloxacin (Ahmed et al., 2008; Chio et al., 2009; Kato et al., 
2008) are also substrates for the MRP2 transporter. 
 
Because MRP2 has such diverse substrate specificity, it can alter the intracellular 
concentration of many therapeutically used agents and toxicologically relevant 
xenobiotics.  For example, there was a 10-fold decrease in the rate of biliary excretion of 
spiramycin, an antibiotic, in Mrp2 knockout mice (Xianbin et al., 2007).  Other studies 
showed a 1.7-1.9-fold increase in the plasma levels of the food-derived carcinogens IQ 
(2-amino-3-methylimidazo[4,5-f]quinoline) and  PhIP (2-amino-1-methyl 6-
phenylimidazo[4,5- b]pyridine), increases in serum levels of fexofenadine, and increases 
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in the serum levels of methotrexate in Mrp2
-/-
 mice versus wild-type mice (Matsushima et 
al., 2008; Vlaming et al., 2006).  Mrp2-deficient mice have decreased total bilirubin and 
glutathione in bile, and increased levels of bilirubin in urine, indicating that urinary 
excretion may serve as an alternate excretion pathway for certain compounds in these 
mice (Vlaming et al., 2006).  Mrp2-deficient rats had an 8.5-fold increase in the serum 
concentration of ezetimibe, an anti-hyperlipidemic, which was associated with an 
increase in urinary elimination and decrease in fecal elimination (Oswald et al., 2006).  
Likewise, methotrexate serum concentrations were increased and biliary concentrations 
were decreased in mice lacking Mrp2 (Vlaming et al., 2006).   
 
Since many drugs are substrates for the same transporter, there is an increased risk 
of serious adverse effects when these proteins are inhibited at the same time.  It was 
shown that the coadministration of the anti-inflammatory drugs indomethacin and 
sulfasalazine, both substrates for MRP2, increased the absorption and decreased the 
elimination of sulfasalazine in the small intestine (Dahan et al., 2010).  Additionally, a 
wide variety of nonsteroidal anti-inflammatory drugs, such as salicylate, ibuprofen, 
tolmetin, naproxen, sulindac, etodolac, indomethacin, piroxicam, ketoprofen, diclofenac, 
celecoxib, and phenylbutazone, all inhibit MRP2-mediated methotrexate transport in 
vitro (El-Sheikh et al., 2007).  The pretreatment of dexomethasone in rats reduced the 
total clearance of methotrexate by 33%, suggesting that multiple substrates may decrease 
the ability of MRP2 to eliminate drugs (Fuksa et al., 2010).  This coadministration of 
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MRP2 substrates or inhibitors could lead to the elongated or shorted effects of the drug, 
and these types of drug-drug interactions need to be further investigated.    
 
Assessing the transport of highly prescribed pharmaceuticals via MRP 
transporters either alone or in mixtures is important to determine the potential for drug-
drug interactions.  In the present study, we examined fosinopril, an angiotensin 
converting enzyme (ACE) inhibitor, and loratadine and desloratadine, both 
antihistamines, to determine if they were substrates for the MRP transporters, and if so, 
whether they could alter the transport and toxicity of one another. 
 
2. Methods: 
2.1 Cell Culture 
Marin-Darby canine kidney (MDCK) cells and MDCK cells transfected with the 
human MRP1 and MRP2 gene were a gift from Piet Borst (Netherlands Cancer Institute).  
Cells were grown in DMEM containing 10% FBS, 1% L-glutamine, and 1% 
penicillin/streptomycin at 37ºC in a 5% CO2 atmosphere.  The cells were passaged 
approximately every 4 days and were terminated at passage number 20.   
 
2.2 Drug selection and cell viability assays 
The drug index database (http://www.rxlist.com/top200.htm), which lists the 200 
most-prescribed medications in the U.S, was scanned to determine potential MRP1 and 
MRP2 substrates based upon molecular weight, excretion into the feces, and the 
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formation of glucuronide conjugates.  Based upon these criteria and preliminary 
experiments, fosinopril, loratadine, and desloratadine were selected to determine if they 
were substrates for the MRP transporters.  Cell viability experiments were performed by 
seeding 6x10
3
 cells per well into 96 well plates.  Cells were allowed to attach overnight 
and the next day, the medium was replaced with 100µL medium containing the drug of 
interest.  The cells were incubated for 3 days with six increasing concentrations (n=5 
wells per concentration) of vincristine (American Radiolabeled Chemicals, Saint Louis, 
MO), loratadine (Sigma, St. Louis, MO), fosinopril (Sequoia Research Products Ltd, 
Pangbourne, United Kingdom), desloratadine (Sigma), or methotrexate (American 
Radiolabeled Chemicals).  The MTS assay (Promega, Madison, WI) was used to assess 
cell viability by spectrophotometry at 490nm.  Each experiment was repeated two to three 
times.  LC50 values were determined using dose response curves produced in Graphpad. 
 
2.3 Cellular Accumulation and Efflux 
Cells were seeded into a 6 well plates at 1.8x10
5
/well (4 wells/cell line) and were 
allowed to become confluent over 3 days.  After confluence, the medium was aspirated 
off and pre-incubated with serum-free medium containing 100µM verapamil (Sigma) for 
30 minutes.  After pre-incubation, media was replaced with serum-free medium 
containing 100µM verapamil and 34.2µM desloratadine (the LC25), 42µM loratadine (the 
LC25), 100µM fosinopril (the LC95), 500nM [
3
H] vincristine (0.167µCi/well, American 
Radiolabeled Chemicals), or 1µM [
3
H] methotrexate (0.167µCi/well, American 
Radiolabeled Chemicals).  Cells were allowed to accumulate the drug for time periods 
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ranging for 0 to 6 hours.  At the varying time point, cells were washed and scraped into 2 
mL PBS.  For [
3
H] vincristine and [
3
H] methorexate, the amount of compound remaining 
in the cells was determined by scintillation counting. 
 
For desloratadine and loratadine, 400µL of 1M NaOH was added (Amini et al., 
2004) and for fosinopril, 400µL of 1M HCl was added (Cui, 2007).  All three drugs were 
extracted into butanol/hexane (2:98), evaporated under nitrogen, and then the extract was 
resuspended in methanol.  The aqueous portion was used to determine protein 
concentration of the cells.  Efflux experiments were carried out similarly, except after 
medium removal and washing, serum-free medium was placed back into each well, and 
the cells were allowed to efflux their accumulated drugs for 0-30 minutes. The amount of 
drug remaining in the cell was determined by a Waters HPLC equipped with a dual 
absorbance wavelength detector and a Hypersil C18 Column (ES Industries, West Berlin, 
NJ).  For loratadine and desloratadine, detection was at 247nm, while detection for 
fosinopril was at 220nm.  The mobile phase for loratadine and desloratadine was 
acetonitrile, 20mM dihydrogen phosphate, and triethylamine (43:57:0.02, v/v/v, pH 2.4) 
with a flow rate of 1mL/mim (El-Sherbiny, 2007).  The mobile phase for fosinopril was 
acetonitrile, water, and ortho- phosphoric acid (4000:15:2, v/v/v) with a flow rate of 
1mL/min (Kirschbaum, 1990).   
 
2.4 Altered enzyme and gene expression in fosinopril dosed mice  
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Male FVB mice (n=10) were obtained from Taconic and individually housed until 
9 weeks of age.  All experiments were approved by the IACUC at Clemson University.  
Mice were gavaged for 3 days with water or 100mg/kg fosinopril (n=5 mice/group).  The 
animals were euthanized 6 hours after the final gavage, and blood, livers, small intestines, 
gallbladders, and kidneys were collected.  Serum was prepared from the blood and stored 
at -20
o
C, while the organs were weighed and frozen at -80
o
C until analysis.  Serum was 
used to determine total bilirubin, ALT, and AST concentrations (Johnson & Johnson’s 
VT250 Automatic Chemical Analyzer), while livers and kidneys were used to determine 
transporter and phase II enzyme expression by QPCR.   
 
2.5 QPCR  
RNA was isolated from liver and kidneys of the mice using TriReagent (Sigma-
Aldrich, St. Louis, MO).  Two micrograms RNA was incubated with 0.2mM 
deoxynucleotide mix, 2ng random hexamers, and 200U MMLV reverse transcriptase 
(Promega, Madison, WI) for 1 hour at 37°C to prepare cDNA.  The expression of Mrp1, 
Mrp2, Mrp3, Mrp4, Bsep, UGT1A, and UGT2B was quantified by QPCR using SYBR 
green (Bio-Rad, Hercules, CA) and the appropriate primers (Table 1).  Standards were 
prepared specifically for each gene to be analyzed using PCR and then purified using the 
Qiagen PCR purification kit (Qiagen, Valencia, CA).  The concentration of the purified 
sample of cDNA was determined by spectrophotometry, and used to make serial 
dilutions.  Samples and standards were run in triplicate, and GAPDH was used as a 
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housekeeper gene.  Fold changes were determined by dividing gene levels of mice that 
received fosinopril by wild-type mice gene levels.   
 
2.6 Drug disposition in Mrp2
-/- 
mice 
Male FVB (control) and Mrp2 knockout mice (n=10 of each strain) were obtained 
from Taconic and individually housed until 9 weeks of age.  Five mice from each strain 
received 50mg/kg [
3
H] methotrexate in saline via tail vein injection (Vlaming et al., 
2006), and five mice from each strain received 50mg/kg [
3
H] methotrexate via tail vein 
injection plus 100mg/kg fosinopril via gavage.  Mice were euthanized 1 hour later, since 
the half-life of methotrexate in mice is ~30 minutes (Sani et al., 2010) and the half-life of 
fosinopril in humans is ~12 hours (reviewed in Murdoch et al., 1992).  Blood was 
collected and spun to collect serum.  Intact livers, kidneys, small intestines, colons, and 
gallbladders with contents were collected and homogenized in PBS.  An aliquot of the 
homogenate or serum was used for scintillation counting to determine the amount of 
methotrexate in each organ.   
 
2.7 Data Analysis 
Samples from each group were averaged and significant differences were 
determined by ANOVA, followed by the appropriate post-hoc test, or by Student’s t-test 





3.1 Drug sensitivity 
The sensitivity of MDCK cells transfected with MRP1 and MRP2 to 3 high-use 
pharmaceuticals, fosinopril, loratadine, and desloratadine was assessed, using the known 
substrates vincristine and methotrexate as positive controls.  MRP1-overexpressing cells 
were 1.4-fold less sensitive to the toxicity of loratadine, while desloratadine showed no 
differences in sensitivity (Table 2).  In contrast, MRP1-overexpressing cells are 2.0-fold 
and MRP2 are 2.4-fold less sensitive for fosinopril than controls (Table 2).  These results 
suggest that loratadine and fosinopril are potential substrates for MRP transporters. 
 
3.2 Drug efflux assays 
Preliminary experiments were conducted to determine the appropriate 
accumulation time for each compound, which was 2 hours for fosinopril, 4 hours for 
vincristine, 1 hour for loratadine, and 6 hours for desloratadine and methotrexate.  After 
cells were loaded with the drug, their rate of efflux was examined.  Vincristine was 
effluxed out of the MRP1-overexpressing cells more rapidly, with 56% of the compound 
remaining in MRP1 cells after 20 minutes, compared to 85% remaining in the MDCK 
cells (Figure 1A).  The other positive control, methotrexate, showed 1.5-fold less 
accumulation in MRP2 cells compared to controls (data not shown).  For fosinopril, the 
MRP2 cells only retained 13 % of their accumulated fosinopril while the MDCK cells 
retained 60 % (Figure 1B).  While MRP1 and MRP2 showed no real differences in their 
ability to efflux loratadine (Figure 1C),  MRP2-overexpressing cells effluxed 
desloratadine significantly more rapidly, as 56% of the accumulated desloratadine 
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remained in MRP2-overexpressing cells after 20 minutes compared to 66% retention in 
the MDCK cells (Figure 1D).   
 
Since fosinopril appeared to be a substrate for MRP2, we coincubated cells with 
fosinopril and either loratadine, desloratadine, or methotrexate to determine if the second 
drug would increase the retention of fosinopril.  When fosinopril was combined with 
desloratadine, its retention was increased by 2-fold (Figure 2A), with loratadine, its 
retention was increased by 4.7-fold (Figure 2B), and with methotrexate, the retention was 
increased by 2-fold (Figure 2C). 
 
3.4 mRNA expression and serum chemistry in mice dosed with fosinopril 
FVB mice were treated with fosinopril for 3 days to determine whether phase II 
enzymes and transporters gene expression would be induced.  There was a 2.1-fold 
increase in liver Bsep mRNA expression (Table 3), but no other changes in enzyme gene 
expression were seen.  Additionally, there were no significant differences in serum AST, 
ALT, or total bilirubin (data not shown).  
 
3.5 Altered drug disposition in Mrp2-/- mice 
Preliminary drug disposition experiments indicated that fosinopril serum 
concentrations were below the HPLC detection limits.  Therefore, [
3
H]methotrexate was 
used to determine if fosinopril co-administration would alter methotrexate disposition.   
When Mrp2 was lacking, fosinopril increased the accumulation of methotrexate in the 
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liver by 2.1-fold and decreased methotrexate levels in the intestine by 1.5-fold (Figures 
3A and B).  While the gallbladder accumulated 2.9-fold less methotrexate when 
combined with fosinopril, there were no differences between the wild-type and knockout 
mice (Figure 3E).  In both the serum and kidney, there was a significant 2.9-fold and 3-
fold increase, respectively, in methotrexate accumulation in the Mrp2 knockout mice.  
The co-administration of fosinopril appeared to increase accumulation in the serum, 
although this was not quite statistically significant (Figure 3D).  However, fosinopril 
coadministration did increase accumulation in the kidney (Figure 3C).  
 
4. Discussion  
The present study indicates that fosinopril is a substrate for the MRP2 transporter 
based upon reduced toxicity to and an increased rate of elimination from MRP2-
overexpressing cells, as well as altered disposition in Mrp2-/- mice.  Additionally, 
fosinopril coincubation with other substrates for the MRP2 transporter increases 
fosinopril retention and reduces its elimination, suggesting a potential for drug-drug 
interactions.    
 
Fosinopril is an ACE inhibitor, which is used in patients with cardiovascular 
disease and hypertension. Approximately 3,155,000 prescriptions a year are written for 
fosinopril, making it one of the most highly prescribed medications for hypertension 
(http://www.rxlist.com/top200.htm).  Our data indicates that fosinopril is a substrate for 
MRP2, since it is both 2-fold less toxic to MRP2-overexpressing cells and is eliminated 
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at a 4-fold faster rate in cells that overexpress MRP2 versus control cells.  Like 
fosinopril, other ACE inhibitors such as enalapril and temocapril were previously shown 
to be substrates for the MRP2 transporter in vitro and in vivo (Ishizuka et al., 1997; Liu et 
al., 2006).  For example, in EHBR rats, which do not express functional Mrp2 protein, 
the biliary excretion rate of enalapril is essentially 0 (Liu et al., 2006).   Additionally, 
studies have shown that temocapril was taken up into Mrp2-expressing membrane 
vesicles to 3-fold higher levels than vesicles from EHBR rats, which lack Mrp2.  
Similarly, in vivo studies show that temocapril serum levels were approximately 2- to 5-
fold higher in rats lacking Mrp2, which correlated with a 3-fold reduction in its biliary 
elimination rate (Ishizuka et al., 1997; Takada et al., 2004).  Likewise, the current study 
indicates that fosinopril can increase methotrexate levels in the serum by 3- to 5-fold in 
mice lacking Mrp2, which is similar in magnitude to the above studies using rats lacking 
Mrp2.  However, many other ACE inhibitors including benazepril, cilazapril, delapril, 
trandolapril, and imidapril are not substrates for Mrp2 (Ishizuka et al., 1997; Shionoiri et 
al., 2001).    
 
Fosinopril, enalapril, and temocarpil are all known to be predominantly 
eliminated in the bile, while most other ACE inhibitors are eliminated in the urine 
(Murdoch and McTavish, 1992; Suzuki et al, 1993).  Although the reasons for this high 
propensity towards biliary excretion are unclear, it has been suggested that the carboxyl 
groups within their chemical structures enable these three ACE inhibitors to be substrates 




Along with its transport by MRP2, studies have revealed that fosinopril can cause 
cholestatic jaundice and liver failure in a short period of time after starting treatment 
(Chou et al., 2008; Nunes et al., 2001).  Similarly, enalapril has also been shown to 
induce cholestasis in some patients (Hartleb et al., 2002; Muela et al., 2002; Todd et al., 
1990).  These clinical findings add further credence to the ability of MRP2 to transport 
fosinopril, symptoms of jaundice and cholestasis are also seen in rats and humans that 
have mutations in MRP2 (Paulusma et al., 1996; Paulusma et al., 1997).   
 
Next, we investigated changes in fosinopril elimination in the presence of a 
second drug. There are 2-, 5-, and 2-fold increased levels of fosinopril that remain in cells 
after coincubation with methotrexate, loratadine, and desloratadine, respectively.  This 
indicates that the two drugs may be competing for elimination.  Other studies have shown 
that dexomethasone can reduce the total clearance of methotrexate by 33% in rats, 
showing that the use of multiple pharmaceuticals that are substrates for the same 
transporter can decrease the clearance of the drugs (Fuksa et al., 2010).  The 
coadministration of indomethacin and sulfasalazine, both substrates for MRP2, decreased 
the elimination of sulfasalazine in the small intestine by 7.5-fold (Dahan et al., 2010).  
Additionally, a wide variety of nonsteroidal anti-inflammatory drugs, such as salicylate, 
ibuprofen, tolmetin, naproxen, sulindac, etodolac, indomethacin, piroxicam, ketoprofen, 
diclofenac, celecoxib, and phenylbutazone all inhibit MRP2-mediated methotrexate 
transport in vitro (El-Sheikh et al., 2007).  The drug-drug interaction that may result 
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could alter toxicity of one or more of the compounds, and may also increase or decrease 
the desired therapeutic effects.   
 
Interestingly, the coincubation of loratadine and fosinopril resulted in a 5-fold 
increase in fosinopril retention compared to the 2-fold increase with either methotrexate 
or desloratadine.  The reasons for this are unclear, but may be due to loratadine acting as 
an inhibitor of MRP2 rather than a substrate, as the efflux rate of loratadine alone was not 




H]methotrexate and fosinopril were coadministered to Mrp2-/- mice, since 
methotrexate elimination is reduced in Mrp2 knockout mice (Vlaming et al., 2006).  Our 
study indicated that when methotrexate was given alone, its levels were increased by 3-
fold in the kidney and 2.9-fold in the serum of mice lacking Mrp2. This is consistent with 
what others have seen, with a 2.2-fold increase in  methotrexate levels in the serum 
(Vlaming et al., 2006), and ~2-fold increase in levels of methotrexate in the kidney of 
Mrp2 knockout mice (Vlaming et al., 2008).  These other studies also reported a 
significant shift from fecal to urinary elimination of methotrexate in mice lacking the 
Mrp2 transporter (Vlaming et al., 2008).  Similar findings have been reported for other 
compounds in Mrp2-/- mice.  For example, bilirubin levels are increased by 5-fold in the 




When fosinopril is given in combination with methotrexate in mice lacking Mrp2, 
fosinopril increased the accumulation of methotrexate in the liver by 2.1-fold.  This 
change was expected because of the high expression of Mrp2 in the liver, and since Mrp2 
is the predominant transporter that eliminates fosinopril and methotrexate (Keppler et al., 
1997; Vlaming et al., 2006).  Additionally, the 1.5-fold decrease of methotrexate in the 
intestines of mice lacking the Mrp2 protein, when given in combination with fosinopril, 
suggests that Mrp2 is involved in the biliary secretion of both methotrexate and 
fosinopril.  Other studies have also reported a 2.3-fold decrease in intestinal levels of 
methotrexate (Vlaming et al., 2006; Vlaming et al., 2009).  This increase in methotrexate 
concentrations in the liver, coupled with a decrease in intestinal concentrations, suggests 
that fosinopril coadministration is causing a reduction in fecal elimination.  In the 
absence of Mrp2, there was a 3-fold and 2.9-fold increase in methotrexate levels in the 
serum and kidney, respectively, when methotrexate was coadministered with fosinopril.  
This again, suggests that when Mrp2 is lacking, fosinopril elimination shifts from the 
feces to the urine.  Although we did not see changes in mRNA expression in FVB mice 
when treated with fosinopril, one possibility is that fosinopril is also a substrate for Mrp3, 
which resulted in its movement from the liver into the serum.   It is known that MRP2, 
MRP3 and Bcrp can transport methotrexate and can all compensate for loss of one or 
more of the transporters in the liver (Doyle et al., 2003; Masuda et al., 1997; Vlaming et 
al., 2008; Vlaming et al., 2009; Volk et al., 2002; Zeng et al., 2001).  Although MRP1, 
MRP4, MRP5 and P-gp can transport methotrexate in vitro, these other transporters do 
not appear to play a significant role in the elimination of methotrexate (Chen et al., 2002; 
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De Graaf et al., 1996; Weilinga et al., 2005; Zeng et al., 2001).  From the present study, 
MRP1 does not appear to transport fosinopril and we attempted to minimize the effect of 
P-glycoprotein by using verapamil.  However, we cannot exclude the possibility that 
Mrp3, Bcrp, Mrp4, and/or Bsep may also transport fosinopril.   
 
In conclusion, MRP2 transports fosinopril and its efflux of fosinopril is reduced in 
the presence of other compounds, such as methotrexate.   These findings and the further 
understanding of the ABC-transporters and their role in drug-drug interactions could 
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Table 1 – QPCR primer sets 
Primer Forward 5’to 3’ Reverse 5’ to 3’ Tm (
o
C) 
Mrp1 taatggaagcagacaaggcccaga agaggccagtgcagatacatggtt 60 
Mrp2 atggtcctagacagcggcaagatt ttcacactttcaatgccggcttcc 60 
Mrp3 agaaccaagcatcaaggtcccaga aaggttctcaccaaagccctcaga 60 
Mrp4 caaagctgcaagccacatcctcat agaccaaattgaggcctcggagaa 60 
UGT1A gaaattgctgaggctttgggcaga agagtgtgtgatgaatgcccgagt 60 
UGT2B agttgagacaatgggccaag gttgggtgaggaaactccaa 61 
Bsep gctggtcatcactggagccccc gcagccctcctgtgcttggc 60 




Table 2.  Drug sensitivity in cells overexpressing MRP1 and MRP2   
LC50 Values 
Drugs MDCK MRP1 MRP2 
Loratadine (µM) 87.1±9.0 124.3±13.6
*
 96.9±4.4 
Desloratadine (µM) 44.5±5.9 48.0±9.2 45.7±5.4 














LC50 values + SD are averaged from three to four separate experiments.  Statistical 
differences between control and transfected cell lines (*) were determined by ANOVA 
followed by Tukey’s (p<0.05).  
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Table 3.  mRNA levels in liver and kidneys of mice treated with 100mg/kg fosinopril 
Name Liver (molecules) Kidney (molecules) 






Mrp1 9.4±2.3 12.3±5.6 1.3 109.6±39.9 194.5±197.7 1.8 
Mrp2 1,378±325 1,286±366 0.9 1,317±229 2,462±2,002 1.9 
Mrp3 774.8±301.6 815.8±550.1 1.1 28.6±6.0 55.6±59.7 1.9 
Mrp4 275.6±146.4 335.9±283.8 1.2 11,589±1,359 15,945±13,280 1.4 
Ugt1A 1,798±729 2,139±1,283 1.2 2,940±825 5,240±5,492 1.8 
Ugt2B 65,511±32,965 83,463±58,067 1.3 80,868±24,831 92,016±55,931 1.1 
Bsep 9,830±2641 20,490±11,651 2.1* 247.6±43.5 438.1±304.2 1.8 
The number of molecules + SD are the average of 4-5 mice, each run in triplicate.  
Statistical differences (*) were determined by Student’s t-test (p<0.05).  
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Figure 1.  Efflux of drugs from MDCK, MRP1 and MRP2 cells. 
MDCK (•), MRP1 (∆) and MRP2 (O) cells were allowed to accumulate vincristine (A), 
fosinopril (B), loratadine (C), and desloratadine (D), and then efflux was measured by 
HPLC or scintillation counting as percent remaining in the cell.  Data is presented as the 
average percentage efflux + standard deviation (n=4-12) of the average of two to three 
combined trials.  Statistical analysis was performed by ANOVA followed by Tukey’s 
(p<0.05; A=MRP1 vs. MDCK; B=MRP2 vs. MDCK). 
 
Figure 2.  Fosinopril concentrations remaining in the MRP2 cells are increased 
when a second substrate is present. 
Fosinopril was allowed to accumulate for 2 hours, and then efflux for twenty minutes.  
Fosinopril remaining in the cell was then measured by HPLC.  Controls were dosed with 
100uM fosinopril and mixtures with either 10, 15, 25uM desloratadine (A), loratadine 
(B), or 30, 50nM methotrexate (C), along with 100uM fosinopril, and then analyzed.  
Data is presented as the average percentage efflux + standard deviation (n=4-8) of the 
average of two combined trials.  Statistical differences between fosinopril alone and 








Figure 3.  Fosinopril alters [
3
H] methotrexate disposition in FVB and FVB/Mrp2-/- 
mice.    
FVB and Mrp2-/- mice (KO) were injected with 50mg/kg [
3
H]methotrexate (MTX) with 
or without 100mg/kg fosinopril (Fos).  The amount of [
3
H] methotrexate remaining in the 
organs and serum was measured by scintillation counting; A (liver), B (small intestine), C 
(kidney), D (serum), E (gallbladder), F (colon).  Data is presented as the average 
percentage remaining + standard deviation (n=4-5 mice per group).  Statistical 
differences (*) were determined by Student’s t-test (p<0.05). 
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Figure 1.  



































































































































































































































































































































































































































































































































































5. Conclusion  
In the past few decades, the prescription of multiple pharmaceuticals has become 
commonplace in the United States.  Every year there is more and more potential for 
injuries to occur, due to the lack of knowledge of certain drug-drug interactions.  Some of 
the prominent mechanisms for toxicity and drug-drug interactions for many highly used 
pharmaceuticals are through the MRP transporters.  Expanding our knowledge of these 
transporters and the interactions that may occur when confronted with multiple 
compounds is essential to avoid complications.  We wanted to determine if certain highly 
used pharmaceuticals are substrates for MRP1 and/or MRP2, and if so, whether the co-
administration of these compounds results in reduced elimination and altered toxicity.  In 
conclusion, we have shown in vitro that the MRP2 transporter is one of the major 
transporters of some highly prescribed pharmaceuticals.  We have demonstrated that 
when fosinopril is in the presence of other compounds, either substrates or potential 
inhibitors, concentrations can be increased significantly.  This could lead to serious 
physiological damages and even fatalities.  Our in vivo experiments further supported that 
MRP2 is a key eliminator of methotrexate and fosinopril.  In these experiments we 
demonstrated that the co-administration of methotrexate and fosinopril can lead to 
increased concentration of drugs, and that the absence of the Mrp2 transporter leads to 
even higher concentration in the liver, kidney, and serum.  This is one example of the 
type of drug-drug interactions that can occur when a combination of several 




It can be assumed that repeated use of more than one substrate for the MRP2 
transporter could result in toxic levels of one or all drugs involved.  The respective half 
lives of fosinopril, loratadine, desloratadine and methotrexate are 12, 12, 27 hours and 30 
minutes (reviewed in Murdoch et al., 1992; Sani et al., 2010; www.merk.com). Usually, 
doses taken for adults are 10mg for fosinopril and loratadine once daily, 5mg every other 
day for desloratadine, and 15 to 30mg of methotrexate for a course of 5 days 
(www.merk.com; www.rxlist.com).  Lethalilty in mice was found to occur at 2,600mg/kg 
fosinopril, 5000mg/kg loratadine, 250mg/kg desloratadine and at total dose of 1.5 grams 
of methotrexate (www.rxlist.com).  With regular use, the chances of fosinopril, loratadine 
and desloratadine reaching toxic levels is unlikely, due the very high doses that would 
need to be reached to produce toxic effects.   Due to the high dose treatment of 
methotrexate, the chances of toxic levels of methotrexate being reached in combination 
with one or more of the described drugs is very likely.  The combination with fosinopil 
especially, has shown to increase the concentration of methotrexate remaining in the 
intestine, serum and kidneys of our wild-type mice.  Special care should be taken to avoid 
the use of methotrexate and fosinopril, because of the potential for toxic levels to be 
reached. 
 
To better explain how the body reacts to and regulates the potential high 
concentration of drugs in the presence of each other, studies to see if certain drugs can 
activate the ligand binding domain of the nuclear receptors, constitutive androstane 
receptor and pregnane X receptor could be conducted.  These nuclear receptors mediate 
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the transcription of genes such as CYP3A4, glucuronosyltransferases, multidrug 
resistance-associated protein 2 and bile salt efflux protein (Kast et al., 2002; Johnson et 
al., 2002; Mackenzie et al., 2003), which are responsible for the metabolism of many 
endogenous compounds, therapeutic drugs, and xenobiotics such as bile salts, 
dexamethasone and phenobarbital (Byrne et al., 2002; Kast et al., 2002; Johnson et al., 
2002).  Activation of nuclear receptors increases the clearance of compounds from the 
body by increasing the levels of proteins responsible for elimination.  Although our 
mRNA data does not support that fosinopril is a ligand for the nuclear receptors, we did 
not examine protein levels of glucuronosyltransferases or ABC transporters, which may 
indeed be upregulated.  One way to quickly examine whether fosinopril activates PXR 
and CAR would be to examine Cyp2b expression, which is the best biomarker for 
activation by these nuclear receptors.   
 
Mice lacking multiple genes is becoming a very useful tool in evaluating the 
metabolism of compounds.  The use of a multiple gene knockout mice could aid in the 
explaining some of the potential compensatory mechanisms that may be occurring to 
reduce concentrations of drugs when one or more transporters are eliminated or impaired.  
For example, when only the Mrp2 protein is absent in mice, total bilirubin in plasma is 
increased by 5-fold (Chu et al., 2006; Vlaming et al., 2006), while mice lacking both the 
Mrp2 and Bcrp transporters have a 7.5-fold increase in plasma levels of bilirubin 
(Vlaming et al., 2009).  These changes in substrate concentrations when more than one 
ABC transporters is absent can also be shown with the drug methotrexate.  In the absence 
45 
 
of Mrp2 alone, plasma concentrations of methotrexate are increased 2.5-fold (Vlaming et 
al., 2006).  When mice lacking the Bcrp transporter are dosed with methotrexate, there is 
a 1.6-fold increase in the concentration of methotrexate in the plasma, while mice lacking 
both the Mrp2 and Bcrp transporters have a 3.3-fold increase in plasma methotrexate 
concentrations (Vlaming et al., 2009).  These studies indicate that in the absence of more 
than one transporter, the concentrations of compounds increase significantly.  In our 
study, we only examined a single gene, Mrp2, and its effect on fosinopril disposition.  
The next step in our research should be to examine whether multiple transporters can 
eliminate fosinopril.  Some potential transporters to examine would include Bsep, since 
its expression was upregulated in the livers of mice dosed with fosinopril.  Another 
transporter to examine is Bcrp, since the double knockout of both Mrp2 and Bcrp 
significantly changes the disposition of methotrexate.  Knowing whether these 2 proteins 
were upregulated and/or could transport fosinopril may help in explaining the some of 
our disposition results, such as why we see increased levels of methotrexate in the 
intestine of mice that received both methotrexate and fosinopril.  The more we can 
uncover about these transporters and how they work in combination with each other will 
help in reducing complications and aid in the more effecting administration of therapeutic 
drugs.   
 
As can be seen, the metabolism of many pharmaceuticals is a very complex 
system and the further study of these potentially dangerous drug-drug interactions that 
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occur between highly prescribed pharmaceuticals and the physiologic changes that result 
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